FDA takes steps to withdraw approval of the swine drug carbadox due to safety concerns

Today, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) took the first step toward rescinding its approval of the use of carbadox to treat swine because the drug may leave trace amounts of a carcinogenic residue.
Source: FDA Press Releases